drugset / Trial / NCT00406315

Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone

NCT00406315

Phase 4 Completed 255 enrolled Viatris Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to evaluate change in weight as a result of switching from quetiapine to ziprasidone, in subjects with schizophrenia or schizoaffective disorder who have failed to achieve a satisfactory clinical response to quetiapine due to lack of efficacy or poor tolerability.

Timeline

Start
2006-11
Primary completion
2008-12
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Ziprasidone Small molecule 40 mg
Subject Ziprasidone Small molecule 60 mg
Subject Ziprasidone Small molecule 80 mg